Periostin and tumor-stroma interactions in non-small cell lung cancer

Nitsche,Ulrich; Stangel,Daniela; Pan,Zheng; Schlitter,Anna  Melissa; Esposito,Irene; Regel,Ivonne; Raulefs,Susanne; Friess,Helmut; Kleeff,Jörg; Erkan,Mert

doi:10.3892/ol.2016.5132

Periostin and tumor-stroma interactions in non-small cell lung cancer

Authors:
- Ulrich Nitsche
- Daniela Stangel
- Zheng Pan
- Anna Melissa Schlitter
- Irene Esposito
- Ivonne Regel
- Susanne Raulefs
- Helmut Friess
- Jörg Kleeff
- Mert Erkan
View Affiliations

Affiliations: Department of Surgery, Klinikum Rechts Der Isar, Technical University of Munich, D‑81675 Munich, Germany, Institute of Pathology, Technical University of Munich, D‑81675 Munich, Germany, Institute of Pathology, Medical University of Innsbruck, A‑6020 Innsbruck, Austria, Department of Surgery, Koc University School of Medicine, Koc University Hospital, 34010 Istanbul, Turkey
Published online on: September 14, 2016 https://doi.org/10.3892/ol.2016.5132
Pages: 3804-3810
Copyright: © Nitsche et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer‑associated mortality globally. Interactions of the cancer cells with the tumor microenvironment are essential carcinogenic features for the majority of solid tumors, such as pancreatic cancer. The present study investigated the role of stromal activation in NSCLC and analyzed the surgical specimens of 93 patients by immunohistochemistry with regard to periostin (an extracellular matrix protein), α‑smooth muscle actin (α‑SMA; a marker of myofibroblasts) and cluster of differentiation 31 (CD31; a marker of endothelial cells), and the activated stroma index. There was a trend towards reduced overall survival for patients with high periostin expression (hazard ratio, 1.80; 95% confidence interval, 0.99‑3.27; P=0.050). No significant correlations with overall survival were identified for α‑SMA (P=0.930), CD31 (P=0.923), collagen (P=0.441) or the activated stroma index (P=0.706). In a multivariable analysis, the histological tumor subtype, tumor stage, lymph node involvement and resection status were independent prognostic factors in NSCLC, but none of the investigated immunohistochemical markers were prognostic factors. Thus, the tumor microenvironment and stroma activation did not prove to be of prognostic relevance for lung cancer, as it has been previously described for pancreatic cancer. Other markers of the microenvironment of NSCLC may be of higher prognostic value, pointing towards tumor‑type specific effects.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
3	Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG and Shepherd FA: Non-small-cell lung cancer. Lancet. 378:1727–40. 2011. View Article : Google Scholar : PubMed/NCBI
4	Heukamp LC and Büttner R: Molecular diagnostics in lung carcinoma for therapy stratification. Pathologe. 31:22–28. 2010.(In German). View Article : Google Scholar : PubMed/NCBI
5	Ferlay J, Autier P, Boniol M, Heanue M, Colombet M and Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 18:581–592. 2007. View Article : Google Scholar : PubMed/NCBI
6	El-Nikhely N, Larzabal L, Seeger W, Calvo A and Savai R: Tumor-stromal interactions in lung cancer: Novel candidate targets for therapeutic intervention. Expert Opin Investig Drugs. 21:1107–1122. 2012. View Article : Google Scholar : PubMed/NCBI
7	de Visser KE, Eichten A and Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 6:24–37. 2006. View Article : Google Scholar : PubMed/NCBI
8	Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar : PubMed/NCBI
9	Bremnes RM, Dønnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, Camps C, Marinez I and Busund LT: The role of tumor stroma in cancer progression and prognosis: Emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol. 6:209–217. 2011. View Article : Google Scholar : PubMed/NCBI
10	Dunér S, Lindman J Lopatko, Ansari D, Gundewar C and Andersson R: Pancreatic cancer: The role of pancreatic stellate cells in tumor progression. Pancreatology. 10:673–681. 2010. View Article : Google Scholar : PubMed/NCBI
11	Kalluri R: Basement membranes: Structure, assembly and role in tumour angiogenesis. Nat Rev Cancer. 3:422–433. 2003. View Article : Google Scholar : PubMed/NCBI
12	Erkan M, Michalski CW, Rieder S, Reiser-Erkan C, Abiatari I, Kolb A, Giese NA, Esposito I, Friess H and Kleeff J: The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 6:1155–1161. 2008. View Article : Google Scholar : PubMed/NCBI
13	Erkan M, Kleeff J, Gorbachevski A, Reiser C, Mitkus T, Esposito I, Giese T, Büchler MW, Giese NA and Friess H: Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology. 132:1447–1464. 2007. View Article : Google Scholar : PubMed/NCBI
14	Kanno A, Satoh K, Masamune A, Hirota M, Kimura K, Umino J, Hamada S, Satoh A, Egawa S, Motoi F, et al: Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells. Int J Cancer. 122:2707–2718. 2008. View Article : Google Scholar : PubMed/NCBI
15	Morra L and Moch H: Periostin expression and epithelial-mesenchymal transition in cancer: A review and an update. Virchows Arch. 459:465–475. 2011. View Article : Google Scholar : PubMed/NCBI
16	Hong LZ, Wei XW, Chen JF and Shi Y: Overexpression of periostin predicts poor prognosis in non-small cell lung cancer. Oncol Lett. 6:1595–1603. 2013.PubMed/NCBI
17	Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Büchler MW, Giese NA and Friess H: Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene. 24:4421–4432. 2005. View Article : Google Scholar : PubMed/NCBI
18	Michalski CW, Shi X, Reiser C, Fachinger P, Zimmermann A, Büchler MW, Di Sebastiano P and Friess H: Neurokinin-2 receptor levels correlate with intensity, frequency, and duration of pain in chronic pancreatitis. Ann Surg. 246:786–793. 2007. View Article : Google Scholar : PubMed/NCBI
19	Saville DJ: Multiple comparison procedures: The practical solution. Am Stat. 44:174–180. 1990. View Article : Google Scholar
20	Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, Moch H and Kristiansen G: Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res. 14:7430–7437. 2008. View Article : Google Scholar : PubMed/NCBI
21	Yan W and Shao R: Transduction of a mesenchyme-specific gene periostin into 293T cells induces cell invasive activity through epithelial-mesenchymal transformation. J Biol Chem. 281:19700–19708. 2006. View Article : Google Scholar : PubMed/NCBI
22	Kim CJ, Yoshioka N, Tambe Y, Kushima R, Okada Y and Inoue H: Periostin is down-regulated in high grade human bladder cancers and suppresses in vitro cell invasiveness and in vivo metastasis of cancer cells. Int J Cancer. 117:51–58. 2005. View Article : Google Scholar : PubMed/NCBI
23	Yoshioka N, Fuji S, Shimakage M, Kodama K, Hakura A, Yutsudo M, Inoue H and Nojima H: Suppression of anchorage-independent growth of human cancer cell lines by the TRIF52/periostin/OSF-2 gene. Exp Cell Res. 279:91–99. 2002. View Article : Google Scholar : PubMed/NCBI
24	Choi H, Sheng J, Gao D, Li F, Durrans A, Ryu S, Lee SB, Narula N, Rafii S, Elemento O, et al: Transcriptome analysis of individual stromal cell populations identifies stroma-tumor crosstalk in mouse lung cancer model. Cell Rep. 10:1187–1201. 2015. View Article : Google Scholar : PubMed/NCBI
25	Yano T, Tanikawa S, Fujie T, Masutani M and Horie T: Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer. 36:601–609. 2000. View Article : Google Scholar : PubMed/NCBI
26	Giatromanolaki A, Koukourakis MI, Theodossiou D, Barbatis K, O'Byrne K, Harris AL and Gatter KC: Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer. Clin Cancer Res. 3:2485–2492. 1997.PubMed/NCBI
27	Han H, Silverman JF, Santucci TS, Macherey RS, d'Amato TA, Tung MY, Weyant RJ and Landreneau RJ: Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol. 8:72–79. 2001. View Article : Google Scholar : PubMed/NCBI
28	Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Whitehouse RM, Talbot DC, Gatter KC and Harris AL: Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer. Int J Cancer. 74:565–570. 1997. View Article : Google Scholar : PubMed/NCBI
29	Sharma S, Sharma MC and Sarkar C: Morphology of angiogenesis in human cancer: A conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology. 46:481–489. 2005. View Article : Google Scholar : PubMed/NCBI
30	Raica M, Cimpean AM and Ribatti D: Angiogenesis in pre-malignant conditions. Eur J Cancer. 45:1924–1934. 2009. View Article : Google Scholar : PubMed/NCBI